Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Amerise Biosciences (formerly Amradeep Industries) approved unaudited financial results for Q3 and nine months ended December 31, 2025. The company has zero revenue from operations and only 'other income' of Rs. 4.49 lakhs in Q3 and Rs. 17.60 lakhs for 9M FY26, resulting in a loss of Rs. 4.07 lakhs for the nine-month period against a Rs. 9.83 lakh loss a year ago. Total expenses for 9M FY26 stood at Rs. 21.67 lakhs. The board also appointed Mr. Albert Hines (25 years old, ~3 years experience in accounts/finance) as Whole-time Director and CFO, replacing Mr. Dinesh Rathod who resigned citing pre-occupation with other work. The statutory auditor (Bipin & Co.) issued an unqualified limited review report.
The company continues to report no operating revenue, persistent losses, and negative other equity of Rs. 122.71 lakhs, signaling ongoing financial weakness. The sudden CFO change with a young replacement and zero business activity makes this a high-risk, thinly-traded micro-cap that investors should approach with caution.